Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: PALISADE
Logo

American Heart Association

  2
  0

Final ID:

Discussant: PALISADE

  • Shapiro, Michael  ( Wake Forest Univ School of Medicine , Winston Salem , North Carolina , United States )
    • Author Disclosures:
    Michael Shapiro: DO have relevant financial relationships ; Consultant:Amgen:Active (exists now) ; Advisor:Arrowhead:Active (exists now) ; Advisor:Merck:Active (exists now) ; Consultant:Regeneron:Active (exists now) ; Advisor:Ionis:Active (exists now) ; Advisor:Agepha:Past (completed) ; Consultant:Novartis:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP)

Watts Gerald, Hellawell Jennifer, Leeper Nick, Gaudet Daniel, Hegele Robert, Rosenson Robert, Goldberg Ira, Gallo Antonio, Mertens Ann, Baass Alexis, Fu Ran, Muhsin Maan

More abstracts from these authors:
Debate: Should Statins be Started in Young Individuals for Primary Prevention? (Pro)

Shapiro Michael, Bailey Alison

The Evolution from Statins to Monoclonal Antibodies and Antisense Technology for Lipid Lowering

Michos Erin, Crooke Rosanne, Shapiro Michael

You have to be authorized to contact abstract author. Please, Login
Not Available